Doç. Dr. Oğuzcan Kınıkoğlu
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Breast Neoplasms 11 publicationsSource: OpenAlex / PubMed MeSHView publications
- Lung Neoplasms 4 publications
- Carcinoma, Non-Small-Cell Lung 3 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyMedical Oncologysaglik.gov.trFrom source
- InstitutionKartal Dr. Lütfi Kırdar Şehir Hastanesisaglik.gov.trFrom source
- Area of workBreast NeoplasmsExtracted from 11 publications · Model version —From source
- Publications70 publicationsOpenAlex, ORCID, Europe PMCFrom source
- ORCID0000-0001-5983-3291ORCIDFrom source
- Last synchronised5 November 2026 08:56https://lutfikirdareah.saglik.gov.tr/TR-1480911/doktorlarimiz.html#oguzcan-kinikoglusaglik.gov.tr
Scientific work
Publications on Breast Neoplasms
-
Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15062217 PMID 41899145 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study
BMC Cancer, 2026
DOI 10.1186/s12885-026-16037-8 PMID 41987096 Open-access full textSource: OpenAlex
-
Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma
Journal of Cancer Research and Clinical Oncology, 2026
DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Open-access full textSource: OpenAlex
-
Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study
Medicina, 2026
DOI 10.3390/medicina62010099 PMID 41597386 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval
Cancers, 2026
DOI 10.3390/cancers18182987 PMID 42794953 Open-access full textSource: OpenAlex
-
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
Cancers, 2026
DOI 10.3390/cancers18142302 PMID 42512369 Open-access full textSource: ORCID
-
Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study
Cancers, 2026
DOI 10.3390/cancers18071103 PMID 41976326 Open-access full textSource: ORCID
-
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
DOI 10.1007/s12094-026-04228-5 PMID 41670816 Source: Europe PMC